• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

U.S. awards bird flu vaccine contracts

Laidback Al

Well-known member
U.S. awards bird flu vaccine contracts <!-- END HEADLINE --><!-- BEGIN STORY BODY -->Wed Jan 17, 5:36 PM ET


The government awarded contracts Wednesday to three drug makers tasked with developing a vaccine for bird flu using technology that will help stretch the supply of the medicine.
The contracts, valued at $132.5 million, may provide a way for more Americans to have access to a vaccine in the event of a pandemic, said Health and Human Services Secretary Mike Leavitt.
The vaccines would use an immune booster called an adjuvant, which reduces the amount of active ingredient per dose that's necessary to achieve protection from the virus.
The Department of Health and Human Services awarded five-year contracts to GlaxoSmithKline PLC for $63.3 million and to Novartis AG for $54.8 million.
The department also will pay Iomai Corp. $14.4 million to complete preliminary trials of its candidate vaccine. Iomai may receive an additional $114 million upon successful completion of those trials.


http://news.yahoo.com/s/ap/20070117/ap_on_he_me/bird_flu_drugs
 
Back
Top